Literature DB >> 3040601

Down-regulation of the EBV-encoded membrane protein (LMP) in Burkitt lymphomas.

A Hatzubai, M Anafi, M G Masucci, J Dillner, R A Lerner, G Klein, D Sulitzeanu.   

Abstract

A radioimmunoassay (RIA) has been developed and used to determine the expression of LMP-a membrane protein encoded by the LT3 region of the Epstein-Barr virus (EBV) genome-in cell lines of various origins. The RIA was highly sensitive, specific and reproducible. All EBV-negative cell lines were LMP-negative and 18 of 21 EBV-carrying cells were LMP-positive. LMP concentrations varied widely, ranging approximately from less than 4 ng up to 650 ng/mg protein. In several instances comparisons were made between lymphoblastoid (LCLs) and Burkitt lymphoma (BL) cell lines (EBV-positive or EBV-converted sublines of originally EBV-negative BL) originating from the same patient. In all such cases LMP and LMP-specific mRNA levels were higher in the LCLs. Most of the LMP was found in the cytosol fraction, yet this fraction was negative in immunoblotting tests. However, antiserum preincubated with the cytosol lost its ability to react in immunoblotting with membrane LMP, indicating that the 2 LMP forms (membrane and cytosol) are completely cross-reactive.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3040601     DOI: 10.1002/ijc.2910400313

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Processing of the Epstein-Barr virus-encoded latent membrane protein p63/LMP.

Authors:  R Moorthy; D A Thorley-Lawson
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

Review 2.  The Epstein-Barr virus and its association with human cancers.

Authors:  K R Baumforth; L S Young; K J Flavell; C Constandinou; P G Murray
Journal:  Mol Pathol       Date:  1999-12

3.  A synthetic peptide defines a serologic IgA response to a human papillomavirus-encoded nuclear antigen expressed in virus-carrying cervical neoplasia.

Authors:  J Dillner; L Dillner; J Robb; J Willems; I Jones; W Lancaster; R Smith; R Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

4.  Up regulation of the Epstein-Barr virus (EBV)-encoded membrane protein LMP in the Burkitt's lymphoma line Daudi after exposure to n-butyrate and after EBV superinfection.

Authors:  B Contreras-Salazar; B Ehlin-Henriksson; G Klein; M G Masucci
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

5.  Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.

Authors:  F Wang; C Gregory; C Sample; M Rowe; D Liebowitz; R Murray; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

6.  Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1.

Authors:  F Wang; S F Tsang; M G Kurilla; J I Cohen; E Kieff
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

7.  Unimpaired activation of c-Jun NH2-terminal kinase (JNK) 1 upon CD40 stimulation in B cells of patients with X-linked agammaglobulinemia.

Authors:  Cornelia Brunner; Hans Wolfgang Kreth; Hans D Ochs; Volker Schuster
Journal:  J Clin Immunol       Date:  2002-07       Impact factor: 8.317

8.  The Epstein-Barr virus LMP1 interactome: biological implications and therapeutic targets.

Authors:  Mujeeb R Cheerathodi; David G Meckes
Journal:  Future Virol       Date:  2018-12-03       Impact factor: 1.831

9.  Epstein- Barr Virus: Clinical and Epidemiological Revisits and Genetic Basis of Oncogenesis.

Authors:  Abdelwahid Saeed Ali; Mubarak Al-Shraim; Ahmed Musa Al-Hakami; Ian M Jones
Journal:  Open Virol J       Date:  2015-11-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.